摘要
目的：
通过检测各类型急、慢性白血病SALL4/BMI-1基因的表达,分析各类型白血病的SALL4/BMI-1基因表达情况,为白血病的MRD监测探求一种新的路径,协助临床判断疗效、预测复发、指导治疗。
方法：
应用实时荧光定量PCR技术,对处于初诊、完全缓解(complete remission,CR)、复发等不同阶段的60例各类型急、慢性白血病进行SALL4/BMI-1基因的定量检测,并选择10例志愿者(4例正常人、6例非恶性血液病患者)作为对照组。
结果：
1.标准品标准曲线的线性关系良好,重复性良好。
2.SALL4和BMI-1基因在CR的各类型白血病中不表达或低表达,在初诊和复发的各类型白血病中高表达。复发组与初诊组相比,表达量无统计学意义(P>0.05)；初诊组及复发组与CR组相比,初诊组及复发组表达量显著高于完全缓解组(P<0.05)；初诊组及复发组与对照组相比,表达量有显著差异性(P<0.05),完全缓解组与对照组相比无显著差异性(P>0.05)。其中,SALL4基因在CLL、T-ALL、M3、M4中不表达或低表达；BMI-1基因在T-ALL中不表达或低表达。
3.BMI-1与SALL4的表达规律一致,两者表达水平有显著相关性(r=0.825,P<0.01)。
结论：
应用实时荧光定量PCR技术定量检测SALL4/BMI-1基因,对监测白血病患者MRD状态具有临床适用性,对MRD动态监测有重要的临床价值。
Objective:To investigate the expression of SALL4 and BMI-1 mRNA in different kinds of leukemia patients through testing the expression of SALL4 and BMI-1 mRNA in acute and chronic leukemia patients and seek a mew method of monitoring minimal residual disease (MRD), conduce to judge curative effect pretest relapse、guide treatment.
Methods:In this experiment, real-time quantitative reverse transcription PCR (RT-PCR) was used for detecting the expression of SALL4 and BM I-1 mRNA in the mononuclear cells of 60 leukemia patients and 10 normal controls.
Results:The expression of SALL4 n.RNA BMI-1 mRNA in de novo leukemia patients and relapsed patients was higher than that in controls, which significantly decreased at complete remission (CR). The difference between CR group and de novo group and relapsed group was statistically significant (p<0.05). In relapsed patients, the expression of SALL4 mRNA increased, slightly higher than that in de novo leukemia group, but the difference between CR group and de novo group and relapsed group was not statistically significant (p>0.05). The expression pattern of BMI-1 was the same to that of SALL4 except the up-regulation in M3、CLL、M4, and the expression of BMI-1 was positively correlated with that of SALL4 in leukemia (r=0.825,p<0.01).
Conclusion:Testing the expression of SALL4 and BMI-1 mRNA in acute and chronic leukemia patients make sense for monitoring minimal residual disease..
引文
1. AL2BARADIE R,YAMADA K,ST HILAIRE C,etal.Duane radial ray syndrome (Okihiro syndrome)maps to 20q13 and results from mutations in SALL4,a new member of the SAL family[J].Am J Hum Gen2et,2002,71:1195-1199.
2. KOHL HASE J,HEINRICH M,SCHUBERT L,etal.Okihiro syndrome is caused by SALL4 mutations [J].Hum Mol Genet,2002,11:2979-2987.
3. Ma Y,Cui W,Yang J,etal.SALL4,a novel oncogene,is constitutively expressed in human acute myeloid leukemia(AML) and induces AML intransgenic mice.Blood, 2006;108:2726-2735.
4. Cui W,Kong NR,M a Y,et al.Differential expression of the novel oncogene SALL4 in lymphoma.plasma cell myeloma.and acute lymphoblastic leukemia.Mod Pathol, 2007,104:10494-10499.
5. Yang J,Chai L,Liu F,etal.BmI-1 is a target gene for SALL4 in hematopoietic and leukemic cells.Proc Nat1A cad SciUSA,2007,104:10494-10499.
6. FRECER V,MIERTUS J.BOROZDIN W,etal.Mo2 lecular Modeling of c2h2 Zinc Finger Mutation of Pu2 tative Human Transcription Factor SALL4 [J].IEJMD, 2004.3:295-307.
7. ZHANG J,TAM W L,TONGG Q,etal.Sall4 modulates embryonic stem cell plurip-otency and early embryonic development by the transcriptional regulation of Pou-5f1[J].Nat Cell Biol,2006,8:1114-1123.
8. Bohm J,Sustmann C,Wihelm C,etal.SALL4 is directly activated by TCF/L EF in the canonical Wnt signalling pathway.Biochem Biophys Res Commun,2006,348:898-907.
9. Haupt Y,Alexander WS,Barri G,etal.Novel zinc finger gene implicated as myc Colla-borator by retrovirally accelerated lymphomagenesis in Emu-myc transgenic mice, Cell,1991,65(5):753-763.
10. HemenwayCS,HalliganBW,LevvyLS.The Bmi-1 oncoprotein interacts with ding and MPh2:the role of RING finger domains.oncogene,1998,16:2541-2547.
11. Lessard J,Sauvageau G.BM I-1 determines the proliferative capacity of normal and leukemic stem cells.Nature,2003,423 (6937):255-260.
12. CUI W,KONG NR,MA Y,etal.Differential expression of the novel oncogene, SALL4, in lymphoma,plasma cell myeloma,and acute lymphoblastic leukemia [J]. Modern Pthology,2006,19:1585-1592..
13. MiharaK,Chowdhury M,Nakaju N,etal.Bmi-1 is useful as a novel molecular Marker for predicting progression of myelodysPlastic syngrome and patient Prognosis. Blood,2006,107:305-398.
14. Lessard J,Baban S,Sauvageau G.Stage-specific expression of polycomb group genes in human bone marrow cell.Blood,1998,91:1216-1224.
15. Van-der Lugt NM,Domen J,Linder K,etal.Posterior transformation,neurological ab-normalities,and sever hematopoietic defects in mice with a targeted deletion of the bmi-lprotooncogene.GenesDev,1994,(8):757-769.
16. Hosen N.Yamane T,Muijtjens M,Pham K,Clarke MF,WeissmanIL.Bmi-1-green Flu-orescent Protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells.Stem Cells.2007,25(7):1635-44.
17. Masashi Sawa,KazuhitoYamamoto,etal.Bmi-1 is highly expressed in Mo-subtype acute myeloid leukemia.International Journal of Hematology.2005,82(1):42-47.
18. Chowdhury M,Mihara K,Kimura A,etal.Expression of polycomb-group(PcG) Pro-tein BMI-1 predicts prognosis in patients with acute myeloid leukemia.Lukemia. 2007,21(5):1116-22.
19. Merkerova M,Bruchova H,Kracmarova A,etal. Bmi-1 over-expression plays a sec-ondddary role in chronic myeloid leukemia transformation.Leuk Lymphoma.2007, 48(4):793-801.
20. Kemenade FJ van,Raaphorst FM,Blokzijl T.etal.Coexpression of BMI-1 and EZH ploycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.Blood.2001,97:3896-3901.
1. 孙晓东,柴忆欢,曹幼甫,等.儿童白血病发病因素调查研究[J].中国航天医学杂志,2003,12(5)：1-3.
2. 张之南,杨天楹,郝玉书.血液病学[M].北京：人民卫生出版社,2003,971-972.
3. AL2BARADIE R.YAMADA K,ST HILAIRE C.etal.Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4,a new member of the SAL family[J].Am J Hum Gen2et,2002,71:1195-1199.
4. KOHL HASE J,HEINRICH M,SCHUBERT L,etal.Okihiro syndrome is caused by SALL4 mutations [J].Hum Mol Genet,2002,11:2979-2987.
5. Bohm J,Sustmann C,Wihelm C,etal.SALL4 is directly activated by TCF/LEF in the canonical Wnt signalling pathw ay.Biochem Biophys Res Commun,2006,348:898-907.
6. Ma Y,Cui W,Yang J,et al.SALL4,a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML intransgenic mice.Blood, 2006,108:2726-2735.
7. YANG JIANCHANG,LI CHAI,LIU FANG,etal.Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells.[J]. PNAS,2007,19:10494-10499.
8. 陈凤花,王琳,胡丽华,原癌基因BMI-1的研究进展[J].临床血液学杂志,2007,4(4)：189-191.
9. 张之南,沈悌等.血液病诊断及疗效标准.第三版,北京：科学出版社,2007,131-132.
10. Grimwade D.The significance of minimal residual disease in patients witll t(15; 17).Best practice & research.Clinical haematology,2002,1:137-158.
11. FRECER V,MIERTUS J,BOROZDIN W,etal.Mo2 lecular Modeling of c2h2 Zinc Finger Mutation of Pu2 tative Human Transcription Factor SALL4[J].IEJMD,2004, 3:295-307.
12. ZHANG J,TAM WL,TONGG Q,etal.Sall4 modulates embryonic stem cell pluripo-tency and early embryonic development by the transcriptional regulation of Pou5f1 [J].Nat Cell Biol,2006,8:1114-1123.
13. Cui W,Kong NR,Ma Y,eta 1.Differential expression of the novel oncogene SALL4 in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol, 2007,104:10494-10499.
14. Park IK.Qian D.Kiel M,etal.Bmi-1 is required for the maintenance of adult self-renewing hematopoietic stem cells.Nature,2003,423(6937):302-305.
15.袁宏,王楠,李士军等,实时荧光定量PCR检测PML-RARα融合基因的临床应用研究.临床实验诊断研究,2007,30(4)：41O-414.
16.姜艳梅,袁宏,刘新元等.应用实时荧光定量RT-PCR检测急性髓系白血病患者am 11/eto融合基因的临床意义分析[J].中国实验血液学杂志,2009,17(1)：17-22.
17. Balciunaite G,Ceredig R.Massa S,etal,A B220+CD117+CD19-hematopoietic pro-genitor with potent lymphoid and myeloid developmental potential. Eur J Immunol, 2005,35:2019-2030.
18. Hou YH,Srour EF,Ramsey H,etal.Identification of a human B-cell/myeloid common progenitor by the absence of CXCR4.Blood,2005,105:3488-3492.